Analytics for Specialty Pharmacies Competing on Data as Much as Access
Winning access to high-value therapies is hard. Capturing the full revenue from those therapies across two different benefit systems, shifting payer rules, and manufacturer reporting requirements is harder.
SolisRx helps Specialty Pharmacies protect revenue and increase margin though connected dispensing, billing, and payer data + integrated RCM analytics.
SCHEDULE A CONSULTATIONSpecialty Pharmacy Today
The specialty pharmacy market is a rapidly growing, highly concentrated sector. Integrated PBM-owned pharmacies control 70-75 percent of specialty drug volume. Independent specialty pharmacies compete in the remaining 25-30 percent, where the differentiators are clinical expertise, patient support depth, and limited distribution drug (LDD) relationships with manufacturers.
The analytics challenge is threefold. Revenue spans both pharmacy benefit and medical benefit billing, with the boundary depending on therapy, plan design, and administration method. Manufacturer hub requirements and LDD reporting, and 340B reporting create data management overhead. And demonstrating outcomes to manufacturers and payers increasingly requires analytics that dispensing systems weren’t designed to produce.
The Revenue Cycle Complexity Specific to Specialty Pharmacy
The medical versus pharmacy benefit distinction means the same drug can go either direction depending on payer, plan, and administration site. Wrong benefit category means rejection; suboptimal category means lower reimbursement.
White bagging (payers routing specialty drugs through preferred pharmacies instead of buy-and-bill) directly threatens drug margin. For pharmacies with LDD agreements, understanding white bagging substitution risk by therapy requires analytics that dispensing systems don’t provide.
LDD program performance determines competitive position. Manufacturers evaluate on patient access, adherence, hub efficiency, and data quality. Structured analytics documentation is needed to strengthen retention and expansion of LDD agreements.
How SolisRx Supports Specialty Pharmacies
Revenue Cycle Analytics
Flag revenue leakage and protect cashflow
Data integration and unified view for medical and pharmacy benefit claims- Denial analysis focused on benefit-classification errors, prior authorization mismatches, and documentation failures
Learn More
Therapy Mix and LDD Analytics
Prioritize high-margin therapies and partnerships
- Contribution margin by therapy, J-code, and patient cohort
- Revenue-at-risk analysis per LDD agreement
- Adherence metrics for manufacturer reporting
Learn More
Intake Optimization
Automate intake to shorten cycle times
- Benefit investigation and authorization pipeline mapping
- Red flag reporting to optimize prior auth, intake, or reimbursement
- Bottlenecks identification for copay assistance, and manufacturer hub requirements
Learn More
Executive Analytics
Make informed decisions with complete visibility across sites
- Consolidated view spanning both benefit types
- KPI dashboards and board-ready reporting
- Therapy mix trending by LDD, and payer concentration risk monitor
Learn More
Financial modeling for therapy expansion
Base expansion decisions on meaningful analytics
- Analysis of impact of payer mix and adherence impact
- Intelligence on the economics of adding high-value therapies such as bleeding disorder treatments or IVIG
Learn More
M&A Readiness
Stay diligence-ready with robust analytics infrastructure
- Therapy and payer mix analysis
- LDD performance data
- Patient retention metrics prepared for QoE review
Learn More
Frequently Asked Questions
View More Resources
How does white bagging affect our revenue, and how do I quantify it?
White bagging removes drug margin on buy-and-bill therapies and shifts volume toward payer-preferred pharmacies. Quantifying exposure requires identifying which therapy categories are targeted by white bagging policies at major payers, contribution margin per patient, and how many patients are in affected plans. SolisRx builds this as part of therapy mix and payer analytics.
What analytics do we need to protect LDD agreements?
Manufacturers evaluate LDD partners on patient access speed, adherence rates, hub program efficiency, and reporting data quality. A patient-level tracking system monitoring each intake-to-adherence step, producing performance documentation aligned with manufacturer expectations, is the analytical foundation.
What specialty pharmacy financial analytics should I have before a transaction?
Buyers look for: revenue and margin by therapy and LDD agreement over 24+ months, payer mix trending with white bagging and formulary exclusion risk, prior authorization approval rates, patient retention, and reconciliation between dispensing volume and billed revenue.
What exactly does Stategis deliver?
We deliver tailored strategy, financial modeling, tech audits, and growth planning—backed by real execution support, not just recommendations.
What kind of companies do you typically work with?
We partner with venture-backed startups, scaling tech firms, consulting groups, and finance teams—from pre-seed to Series C and beyond.
Do you offer one-off projects or ongoing advisory?
Both. We offer focused sprints for immediate needs and retainer-based or embedded advisory for longer-term transformation.
How long does it take to get started?
We typically begin within 5–7 business days of your initial call, depending on scope and availability.
Is Stategis a good fit for early-stage startups?
Yes—especially if you’re preparing to raise capital, need a financial model, or want clear systems and priorities before scaling.
What industries do you specialize in?
Our core focus areas are SaaS, fintech, consulting, B2B services, and investment-backed ventures—but we’re flexible if there’s a strategic fit.
How long does it take to get started?
We typically begin within 5–7 business days of your initial call, depending on scope and availability.
What kind of companies do you typically work with?
We partner with venture-backed startups, scaling tech firms, consulting groups, and finance teams—from pre-seed to Series C and beyond.
What exactly does Stategis deliver?
We deliver tailored strategy, financial modeling, tech audits, and growth planning—backed by real execution support, not just recommendations.
Do you offer one-off projects or ongoing advisory?
Both. We offer focused sprints for immediate needs and retainer-based or embedded advisory for longer-term transformation.
Is Stategis a good fit for early-stage startups?
Yes—especially if you’re preparing to raise capital, need a financial model, or want clear systems and priorities before scaling.
What industries do you specialize in?
Our core focus areas are SaaS, fintech, consulting, B2B services, and investment-backed ventures—but we’re flexible if there’s a strategic fit.